BLLN vs WGS
BLLN: BillionToOne uses breakthrough single-molecule sequencing technology to detect sparse disease signals in blood with unprecedented precision for prenatal and cancer diagnostics. WGS: GeneDx is a genomic intelligence platform using whole-genome sequencing and AI-powered interpretation to diagnose rare diseases, analyze cancers, and support precision medicine across clinical and research settings.
Side-by-side fundamentals
| Metric | BLLN | WGS | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $127.98 | $60.54 | |
| Market cap as of 2026-07-31 | $6.1B | $1.8B | |
| P/E as of 2026-07-31 | 239.75 | n/a | |
| PEG as of 2026-07-31 | n/a | -0.30 | |
| Net margin as of 2026-07-31 | +6.2% | -17.6% | BLLN higher |
| Gross margin as of 2026-07-31 | +69.5% | +69.6% | WGS higher |
| Operating margin as of 2026-07-31 | +8.2% | -16.4% | BLLN higher |
| ROE as of 2026-07-31 | +7.6% | -27.5% | BLLN higher |
| ROA as of 2026-07-31 | +5.1% | -15.7% | BLLN higher |
| Debt / equity as of 2026-07-31 | 0.20 | 0.38 | BLLN lower |
| Revenue growth (YoY) as of 2026-07-31 | -37.0% | +34.1% | WGS higher |
| Revenue CAGR (3y) SEC XBRL | +106.2% | +22.1% | BLLN higher |
| Beta as of 2026-07-31 | 1.01 | 2.01 | |
| 1-year return as of 2026-07-27 close | n/a | -24.2% |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.